Compare BSX & ELV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSX | ELV |
|---|---|---|
| Founded | 1979 | 1944 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.4B | 85.7B |
| IPO Year | 2010 | 2001 |
| Metric | BSX | ELV |
|---|---|---|
| Price | $42.84 | $388.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 19 |
| Target Price | $93.18 | ★ $383.56 |
| AVG Volume (30 Days) | ★ 19.6M | 1.6M |
| Earning Date | 04-22-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.83% |
| EPS Growth | ★ 55.20 | N/A |
| EPS | 0.90 | ★ 8.00 |
| Revenue | $9,076,000,000.00 | ★ $199,125,000,000.00 |
| Revenue This Year | $11.85 | N/A |
| Revenue Next Year | $10.16 | $3.07 |
| P/E Ratio | ★ $48.31 | $48.48 |
| Revenue Growth | 12.49 | 12.49 |
| 52 Week Low | $43.37 | $273.71 |
| 52 Week High | $109.50 | $426.98 |
| Indicator | BSX | ELV |
|---|---|---|
| Relative Strength Index (RSI) | 25.41 | 48.25 |
| Support Level | N/A | $384.30 |
| Resistance Level | $50.14 | $408.00 |
| Average True Range (ATR) | 1.41 | 10.42 |
| MACD | 0.05 | -2.77 |
| Stochastic Oscillator | 10.87 | 17.38 |
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.